Safety and efficacy of Calsporin&#174; (Bacillus&#160;subtilis DSM&#160;15544) as a feed additive for dogs by G. Rychen et al.
SCIENTIFIC OPINION
ADOPTED: 21 March 2017
doi: 10.2903/j.efsa.2017.4760
Safety and efﬁcacy of Calsporin® (Bacillus subtilis
DSM 15544) as a feed additive for dogs
EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP),
Guido Rychen, Gabriele Aquilina, Giovanna Azimonti, Vasileios Bampidis,
Maria de Lourdes Bastos, Georges Bories, Andrew Chesson, Pier Sandro Cocconcelli,
Gerhard Flachowsky, J€urgen Gropp, Boris Kolar, Maryline Kouba, Secundino Lopez Puente,
Marta Lopez-Alonso, Alberto Mantovani, Baltasar Mayo, Fernando Ramos,
Roberto Edoardo Villa, Robert John Wallace, Pieter Wester, Rosella Brozzi and Maria Saarela
Abstract
Following a request from the European Commission, the EFSA Panel on Additives and Products or
Substances used in Animal Feed was asked to deliver a scientiﬁc opinion on the safety and efﬁcacy of
Calsporin® when used in feed for dogs. The additive contains viable spores of a single strain of
Bacillus subtilis. This species is considered by EFSA to be suitable for the qualiﬁed presumption of safety
(QPS) approach to safety assessment. This approach requires the identity of the strain to be conclusively
established, evidence that the strain is not toxigenic and that it does not show resistance to antibiotics of
human and veterinary importance. The strain was found to meet the criteria for the QPS approach in the
context of previous opinions and since concerns are not expected from other components of the additive,
Calsporin® is presumed safe for all target species, including dogs, and for the environment. In a previous
opinion, the Panel also concluded that the additive is not a dermal/eye irritant or a skin sensitiser but
should be considered a potential respiratory sensitiser. The use of the additive in dogs is considered
unlikely to introduce hazards for users of the product not already considered as part of the ﬁrst
assessment. Therefore, the conclusions reached apply to the current application. Four studies were
supplied aiming at investigating the effects of the supplementation of Calsporin® to the faecal
consistency of dogs. Overall, there is a small but signiﬁcant increase in faecal dry matter content and
beneﬁts seen in a subjective assessment of faecal consistency. However, the biological relevance of
changes of this magnitude for the animal is questionable, as are the practical beneﬁts for the owner.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Regulation (EC) No 1831/20031 establishes the rules governing the Community authorisation of
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an
application in accordance with Article 7.
The European Commission received a request from Calpis Co. Ltd.2 for authorisation of the product
Calsporin®, Bacillus subtilis DSM 15544, when used as a feed additive for dogs (category: Zootechnical
additives; functional group: gut ﬂora stabilisers).
According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the
application to the European Food Safety Authority (EFSA) as an application under Article 4(1)
(authorisation of a feed additive or new use of a feed additive). EFSA received directly from the
applicant the technical dossiers in support of these applications. The particulars and documents in
support of the application were considered valid by EFSA as of 16 February 2015.
According to Article 8 of Regulation (EC) No 1831/2003, EFSA shall determine whether the feed
additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on the safety for
the target animals, consumer, user and the environment and on the efﬁcacy of the product Calsporin®
(Bacillus subtilis DSM 15544), when used under the proposed conditions of use (see Section 3.2.1)).
1.2. Additional information
The additive Calsporin® is a preparation containing viable spores of a single strain of
Bacillus subtilis. EFSA has issued several opinions on the safety and efﬁcacy of this product when used
in chickens for fattening (EFSA, 2006, 2007a), with weaned piglets (EFSA FEEDAP Panel, 2010a), with
turkeys for fattening, ducks, geese, pigeons and other game birds for meat production, ducks, geese,
pigeons, game birds, ornamental and sporting birds for rearing to point of lay, turkeys reared for
breeding and chickens reared for laying (EFSA FEEDAP Panel 2010, 2011b), with laying hens and
minor avian species for laying (EFSA FEEDAP Panel, 2015a) and with ornamental ﬁsh (EFSA FEEDAP
Panel, 2015b).
The additive is currently authorised for use with chickens for fattening,3 weaned piglets,4 chickens
reared for laying, turkeys, minor avian species and other ornamental and game birds,5 and laying hens
and ornamental ﬁsh.5
The species B. subtilis is considered by EFSA to be suitable for the qualiﬁed presumption of safety
(QPS) approach to establishing safety for the target species, consumers and the environment (EFSA,
2007b; EFSA BIOHAZ Panel, 2013). This approach requires the identity of the active agent to be
established and the absence of toxigenic potential and susceptibility to a selected range of antibiotics
to be demonstrated.
2. Data and methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of a technical
dossier6 in support of the authorisation request for the use of Calsporin® (Bacillus subtilis DSM 15544)
1 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in
animal nutrition. OJ L 268, 18.10.2003, p. 29.
2 On 26 January 2016, the applicant communicated the change from Calpis Co. Ltd. to Asahi Calpis Wellness Ltd., represented in
the European Union by Asahi Calpis Wellness Co. Ltd. Europe Representative Ofﬁce. 46 rue Paul Valery, 75116, Paris, France.
3 Commission Regulation (EC) No 1444/2006 of 29 September 2006 concerning the authorisation of Bacillus subtilis C-3102
(Calsporin) as a feed additive. OJ L 271, 30.9.2006, p. 19 plus amendments.
4 Commission Regulation (EU) No 333/2010 of 22 April 2010 concerning the authorisation of a new use of Bacillus subtilis
C-3102 (DSM 15544) as a feed additive for weaned piglets (holder of authorisation Calpis Co. Ltd. Japan, represented in the
European Union by Calpis Co. Ltd. Europe Representative Ofﬁce). OJ L 102, 23.4.2010, p. 19.
5 Commission Regulation (EU) No 184/2011 of 25 February 2011 concerning the authorisation of Bacillus subtilis C-3102
(DSM 15544) as a feed additive for chickens reared for laying, turkeys, minor avian species and other ornamental and game
birds (holder of authorisation Calpis Co. Ltd Japan, represented by Calpis Co. Ltd Europe Representative Ofﬁce). OJ L 53,
26.2.2011, p. 33.
6 FEED dossier reference: FAD-2014-0041.
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as a feed additive. The technical dossier was prepared following the provisions of Article 7 of Regulation
(EC) No 1831/2003, Regulation (EC) No 429/20087 and the applicable EFSA guidance documents.
The European Union Reference Laboratory (EURL) considered that the conclusions and
recommendations reached in the previous assessment are valid and applicable for the current
application.8
2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the safety and the efﬁcacy of Calsporin® is
in line with the principles laid down in Regulation (EC) No 429/2008, the relevant guidance
documents: Guidance on zootechnical additives (EFSA FEEDAP Panel, 2012), Technical guidance on
tolerance and efﬁcacy studies in target animals (EFSA FEEDAP Panel, 2011a), and Guidance on the
assessment of additives intended to be used in pets and other non food-producing animals (EFSA
FEEDAP Panel, 2011b).
3. Assessment
Calsporin® is a preparation of viable spores of Bacillus subtilis DSM 15544 intended for use as a
zootechnical additive (other zootechnical additive) in feed for dogs to exert beneﬁcial effects in their
gastrointestinal tract, leading to an increase in faecal consistency/harder stools.
3.1. Characterisation of the additive9
Calsporin® is a dry free-ﬂowing powder with a minimum declared content of 1 9 1010 colony-forming
units (CFU) of Bacillus subtilis DSM 1554410 per gram of additive. It has the same formulation and
method of manufacture as that considered in previous opinions (EFSA, 2006; EFSA FEEDAP Panel,
2010a,b; EFSA FEEDAP Panel, 2015a). Thus, the data pertaining to impurities, physical properties and
shelf-life assessed in these opinions still apply.
3.2. Stability in pet food
A study was performed to investigate the stability of Calsporin® incorporated in a premixture (not
containing choline chloride) in order to supply the recommended dose in the ﬁnal feed and in two
types of feeds for dogs.11 One of the feeds is described as extruded kibbles (moisture 8%, proteins
32%, fat 19%, minerals 7.5%) mixed with soybean oil containing Calsporin®. The second feed is
described as pelleted kibbles manufactured by mixing the additive with fat in the mixer, then pelleted
at temperatures up to 74°C (moisture 9%, proteins 24%, fat 12%, minerals 7%). The samples were
stored in plastic bags at 18°C in a dark room for 3 (premixture) and 25 months (extruded and pelleted
feed), respectively. No losses (< 0.5 log-values) were observed at the end of the experimental period
for any of the test items.
Another study, intended to mimic domestic use, was performed mixing Calsporin® with moistened
feed (at 2.4 9 108 CFU/kg dry feed, in triplicate), prepared by wetting a dry pelleted feed and then
incubating at 30°C for up to 6 h.12 Half of the samples were subjected to heat treatment to eliminate
vegetative cells. The recovery rates of the four samples showed no losses (< 0.5 log-counts).
Evidence was also provided to show that the viability of the additive was not affected by the form
of compression used in the manufacture of solid treats.13
3.2.1. Conditions of use
The product is intended for use in feed for dogs at a minimum dose of 1 9 109 CFU/kg complete
feedingstuffs.
7 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC)
No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications
and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
8 The full report is available on the EURL website: https://ec.europa.eu/jrc/sites/default/files/FinRep-FAD-2009-0013.pdf
9 This section has been amended following the conﬁdentiality claims made by the applicant.
10 The in-house identiﬁer C-3102 has been used in previous assessments.
11 Technical dossier/Supplementary information October 2016/Annexes IV.4.1.8 and IV.4.1.9.
12 Technical dossier/Supplementary information October 2016/Annex IV.4.1.7.
13 Technical dossier/Supplementary information October 2016/Annex IV.4.1.10.
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It may be administered via dry feed, in the form of top-dressing to be mixed with wet feed, or in
complementary feeds or solid treats.
3.3. Safety
The species B. subtilis is considered by EFSA to be suitable for the qualiﬁed presumption of safety
(QPS) approach to establishing safety for the target species, consumers and the environment. In a
previous opinion (EFSA FEEDAP Panel, 2015a), the identiﬁcation of the strain and compliance with the
QPS qualiﬁcations were conﬁrmed. Therefore, the FEEDAP Panel concluded that Bacillus subtilis
DSM 15544 can be presumed safe for target animals and the environment. The Panel considers these
conclusions to apply also in the current assessment. No concerns are expected from other excipients
present in the product, so Calsporin® is also considered safe for target animals and the environment.
In a previous opinion on the use of Calsporin® in feed for chickens for fattening, the FEEDAP
Panel concluded that the additive is not a dermal/eye irritant or a skin sensitiser but should be considered
a potential respiratory sensitiser (EFSA, 2006). The use of the additive in dogs is considered unlikely to
introduce hazards for users of the product not already considered as part of the ﬁrst assessment.
Therefore, the conclusions reached in the previous assessment apply to the current application.
3.4. Efﬁcacy for dogs
The additive is intended to exert beneﬁcial effects in the gastrointestinal of dogs tract leading to an
increase in faecal consistency/harder stools.
The original dossier included two studies aimed at investigating the effects of the supplementation
of Calsporin® to the faecal consistency in dogs and a literature search including studies performed with
other animal species (e.g. piglets, turkeys for fattening, laying hens). These later studies focused
mainly on the evaluation of the effects of the Calsporin® supplementation on the zootechnical
performance of the animals. Considering the different end-points/effects observed in the major species
and those in dogs, efﬁcacy demonstration in the major species cannot be used to support that in dogs.
The applicant supplied two additional studies in dogs. The four studies are described below. They all
investigate the effect of Calsporin® administration on the characteristics of stools.
The ﬁrst trial is a publication of a study performed in a non-European country (Portella Felix et al.,
2010).14 The study involved 12 dogs (7–8 months old, both sexes, Beagle breed) distributed between
two dietary treatments, with six replicates per treatment: control or Calsporin® added at the minimum
recommended dose, 1 9 109 CFU/kg feed. The additive was mixed with soybean oil and added to a
basal commercial extruded feed for the treatment group. Compliance of the additive with speciﬁcations
and concentration of the additive in feed were conﬁrmed by analysis. Controls received the same basal
feed mixed with the same amount of soybean oil, but without the additive. The treatment diets were
offered once a day to the dogs for 30 days. The dogs were individually housed for the ﬁrst 20 days
and then transferred to metabolic cages (5 days cage adaptation, followed by 5 days of total faeces
collection). Faeces were collected, weighed and subjected to analyses of dry matter, pH, ammonia
content, and score15 and digestibility of nutrients (crude protein, crude ﬁbre, mineral matter and ether
extract). For faecal characteristics, the study design was completely randomised and a split-plot in time
was applied (main plot: treatments; subplot: days), with 5 days of data collection and six dogs per
treatment. Also, for diet digestibility, the study design was completely randomised with two treatments
of six replicates per treatment. Data were subjected to an analysis of variance (ANOVA) and means
were compared using the Tukey–Kramer (faecal characteristics) or Tukey’s test (digestibility
parameters). Signiﬁcant differences were declared at p < 0.05.
Faeces of dogs supplemented with Calsporin® showed signiﬁcantly greater dry matter contents
(Calsporin®: 39.1% vs control: 36.5%, p < 0.05), better faecal scores (Calsporin®: 3.4 vs control: 3.0,
p < 0.05, although the author recognises both as optimal) and lower ammonia content than that from
dogs fed the control diet (Calsporin®: 0.45% vs control: 0.56%, p < 0.05). Diet digestibility, faecal pH
and faecal output were not different between treatments.
The second trial was a double-blind study with 14 puppies from three litters (approximately 8 weeks
old, both sexes, medium-large (German Shepherd) and small breeds (Fox and Hungarian Jagd Terriers))
housed in individual kens.16 Puppies were distributed by sex and initial body weight in two homogeneous
14 Technical dossier/Section IV/Annex IV.3.1.
15 Using a ﬁve point-scale with 1 denoting very soft faeces and 5 shaped, dry and hard faeces.
16 Technical dossier/Section IV/Annex IV.3.2.
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treatment groups. Animals were fed a daily diet composed of approximately two-thirds of wet feed and
one-third of dry feed. Calsporin® or a placebo (based on soybean meal) were added as a top-dressing to
a small portion of the wet feed to guarantee full consumption (100 g Calsporin®/10 kg soybean meal,
to produce a top-dressing of 1 9 108 CFU/g) delivering 1 9 109 CFU/kg complete diet (equivalent to
3–7 9 108 CFU/dog per day, depending on body weight). Compliance of the additive with speciﬁcations
and concentration of the additive in the top-dressing were conﬁrmed by analysis. Faeces were collected
daily to monitor faecal scores,17 ammonia content, moisture and immunoglobulin A (IgA) concentration.
Blood samples were taken from all animals at study start (day 1, to establish baseline values), after
15 days and at the end of the study at day 43 to monitor immune parameters (serum vaccinal titres, IgG
and IgA) and a stress parameter (serum C-reactive protein). Feed intake and body weight were
measured on a weekly basis and general health monitored during the whole experimental period. Data
were analysed with ANOVA considering the treatment as main factor and each dog as the experimental
unit. The model included treatment and gender as main factors. Signiﬁcant differences were declared at
p ≤ 0.10.
Health of puppies was good throughout the study and there was no mortality. No signiﬁcant
differences in growth and food intake were observed between treatments. As regards serum antibody
titres, the only signiﬁcant differences observed were related to lower C-reactive protein values at day
15 in blood samples from the treated animals compared to control animals (Calsporin®: 0.06 vs
control: 0.11 mg/dL, p < 0.0075). As regards faecal parameters, the only signiﬁcant effect was
observed in faecal IgA counts at the end of the trial which were greater in samples from treated
animals compared to samples from control animals (Calsporin®: 6.76 vs control: 3.48 mg/g wet
matter, p < 0.0087).
The third study involved 16 Beagle dogs (4–8 years old, both sexes), individually housed and
evenly distributed (based on sex and weight) between two dietary treatments: control or Calsporin®
supplemented at the minimum recommended dose of 1 9 109 CFU/kg feed.18 Dogs were fed a dry
extruded feed during a 2-week acclimatisation period before being given the experimental diets.
Compliance of the additive with speciﬁcations and concentration of the additive in feed were conﬁrmed
by analysis. Dogs were monitored for weight, feed intake and health status during the entire
experimental period of 28 days. Faecal scores were monitored approximately every 2 days.19 Faecal
samples were collected at several time points (0, 7, 14, 21 and 28 days), and subjected to analyses to
monitor dry matter, pH, and ammonia content (at start, day 7 and end of the study). Data were
analysed using ANOVA. The effect of diet on the studied parameters was analysed considering diet as
ﬁxed effect and with the single dog as experimental unit and as random effect. The factor time (day or
week) was included in the model as a repeated measure. The inclusion of basal values (day or week
zero) as covariate in the model was also considered for faecal parameters in which the effect of the
covariate was signiﬁcant. Signiﬁcant differences were established at p ≤ 0.10.
A small but signiﬁcant decrease in faecal scores (Calsporin®: 2.85 vs control: 3.30 after 4 weeks;
p = 0.01) was detected in Calsporin® treated-animals. Although faecal dry matter content was
increased in the early part of the study (Calsporin: 30.8% vs control: 27.3% at day 7 and Calsporin:
30.9% vs control: 26.4% at day 14; p = 0.021), no differences were observed after 4 weeks (control:
29.1% vs Calsporin: 29.7%). Faecal pH remained normal throughout the study (6.0–6.7) and no
signiﬁcant changes to faecal ammonia content were seen.
The fourth study involved 16 Beagle dogs (4–8 years old, both sexes), individually housed and
evenly distributed (based on sex and weight) between two dietary treatments: control and
Calsporin®.20 Dogs were fed a dry extruded feed without or with Calsporin® at the minimum
recommended dose of 1 9 109 CFU/kg feed) during the 33 days of the study. Compliance of the
additive with speciﬁcations and concentration of the additive in feed were conﬁrmed by analysis. The
dogs were monitored for weight, feed intake and health status overall the experimental period. Faecal
scores were monitored daily.21 Faecal samples were collected at the end of the trial and subject to
analysis of dry matter and ammonia content. Data were analysed according to a completely
randomised design with the diet as effect and the single dog as experimental unit. Student’s t-test was
17 Using a ﬁve point-scale with 1 denoting very soft faeces, 5 denoting dry and hard faeces and 4 as ideal score.
18 Technical dossier/Supplementary information October 2016/Annex IV.3.3.
19 Using a seven point-scale with 1 denoting dry and hard faeces and 7 watery faeces.
20 Technical dossier/Supplementary information October 2016/Annex IV.3.4.
21 Using a ﬁve point-scale with 1 denoting soft stools and formless and 5, well-formed stools, hard and dry.
Calsporin® for dogs
www.efsa.europa.eu/efsajournal 7 EFSA Journal 2017;15(4):4760
used to compare means of body weight, condition score and feed intake and Kruskal–Wallis test to
compare faecal parameters. Signiﬁcant differences were declared at p < 0.10.
Dry matter of faeces of the Calsporin® group was signiﬁcantly greater (denoting harder faeces)
than that of the control group at the end of the experimental period (Calsporin: 33.9% vs control:
30.3%; p = 0.021). Overall, the Calsporin® group showed a signiﬁcantly greater distribution of faecal
score 4 compared to the control (Calsporin: 55.9% vs control: 32%; p < 0.01). However, baseline
values for faecal scores were not recorded. Faecal ammonia content was not inﬂuenced by treatment.
3.4.1. Conclusion on the efﬁcacy for dogs
Overall, there is a small but signiﬁcant increase in faecal dry matter content and beneﬁts seen in a
subjective assessment of faecal consistency. However, the biological relevance of changes of this
magnitude for the animal is questionable, as are the practical beneﬁts for the owner.
3.5. Post-market monitoring
The FEEDAP Panel considers that there is no need for speciﬁc requirements for a post-market
monitoring plan other than those established in the Feed Hygiene Regulation22 and Good
Manufacturing Practice.
4. Conclusions
The active agent fulﬁls the requirements of the QPS approach to the assessment of safety and no
concerns are expected from other components of the additive. Consequently, Calsporin® can be
presumed safe for dogs and for the environment.
The additive is not a dermal/eye irritant or a skin sensitiser but should be considered a potential
respiratory sensitiser. Use of the additive in dogs is considered unlikely to introduce hazards for users
of the product not already considered as part of the ﬁrst assessment.
Overall, there is a small but signiﬁcant increase in faecal dry matter content and beneﬁts seen in a
subjective assessment of faecal consistency. However, the biological relevance of changes of this
magnitude for the animal is questionable, as are the practical beneﬁts for the owner.
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1) CALSPORIN®. Bacillus subtilis C-3102, DSM 15544. Zootechnical feed additive for dogs.
December 2014. Submitted by Calpis Co. Ltd.
2) CALSPORIN®. Bacillus subtilis C-3102, DSM 15544. Zootechnical feed additive for dogs
Supplementary information October 2016. Submitted by Asahi Calpis Wellness Co. Ltd.
3) Comments from Member States.
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